)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Viracta Therapeutics (VIRX) investor relations material
Viracta Therapeutics H.C. Wainwright 26th Annual Global Investment Conference 2024 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 26th Annual Global Investment Conference 2024 summary11 Sep, 2024
Key presentations and announcements
Vireacta Therapeutics presented NanoVal, an oral therapy targeting EBV-associated cancers, with a focus on PTCL, DLBCL, and PTLD lymphomas, as well as nasopharyngeal carcinoma and gastric cancer.
NanoVal demonstrated compelling overall response rates of 60–70% in second-line EBV-positive PTCL patients, with durable responses and manageable side effects.
A clear regulatory path was outlined, targeting an NDA filing in 2026, following FDA guidance to conduct a randomized controlled study alongside the ongoing pivotal Phase II trial.
The solid tumor program is paused pending additional financing or partnership, with dose-ranging work completed and a recommended Phase II dose expected in Q4 2024.
A 23% reduction in force was implemented in August to align resources with strategic priorities.
Industry analysis and market outlook
EBV-associated cancers represent about 2% of global cancer cases, with over 300,000 new patients annually, highlighting significant unmet medical need.
EBV-positive lymphomas have much poorer survival rates compared to EBV-negative cases, with rapid disease progression and limited treatment options.
NanoVal’s novel “kick and kill” mechanism offers a targeted approach, potentially setting a new standard of care for EBV-positive PTCL, especially in second-line treatment.
The company’s data compare favorably to other treatments that have received accelerated approval for PTCL, despite those not being EBV-specific.
Expansion into additional lymphoma subtypes and solid tumors is planned, contingent on future funding or partnerships.
Forward-looking statements and plans
Additional efficacy and safety data from the PTCL Stage 2 expansion cohort will be presented in Q4 2024 and H1 2025.
A randomized controlled study in second-line PTCL is set to begin enrollment in H2 2025, with interim analysis planned for 2026.
NDA submission for NanoVal in EBV-positive PTCL is targeted for 2026, aiming for accelerated approval.
Solid tumor program will resume once additional financing or partnerships are secured.
The company aims to expand NanoVal’s indications to other EBV-associated lymphomas and solid tumors in the future.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Viracta Therapeutics Inc. is a precision oncology company focused on developing treatments for virus-associated cancers. The company's leading product candidate, Nana-val, is an all-oral combination therapy comprising its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Beyond Nana-val, Viracta is exploring the "Kick and Kill" approach for other virus-related cancers, aiming to leverage its expertise in oncology to address the needs of patients with virus-associated malignancies globally. Headquartered in Cardiff-by-the-Sea, California, Viracta Therapeutics Inc.'s shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage